A population of about 2.3 million children living in southern Belarus, northern Ukraine and the most easterly regions of the Russian federation was exposed to significant amounts of radioactive iodine during the Chernobyl accident. The result, less than fifteen years after the accident, is more than 1,000 cases of thyroid cancer, most probably solely attributable to this single release of radioactivity to the environment.

The sensitivity of the child’s thyroid to the carcinogenic effects of radiation represents a significant public health risk in the event of exposure to radioactive iodine. This has been well established. In the most affected area in Belarus, the yearly incidence has risen close to 100 cases per million children, which is more than 100 times the incidence in the general population. It is now generally accepted that this excess has resulted from exposure to the radioactive iodine released in the accident. The Chernobyl accident has demonstrated that significant levels of radioactive iodine can drift hundreds of miles from the site. Another important insight gained from the Chernobyl accident concerns the side effects of stable iodine. In Poland, potassium iodide, as single doses, was given to 10 million children. No serious side effects were seen. The incidence of severe side effects from a single dose of iodine was less than 1 in 10 million in children and less than 1 in a million in adults.

back to top






Thyroid Cancer Incidences In Ukrainian Young Children (Birth - 14yrs)*. The Ukraine was unprotected by potassium iodide.


FDA Recommended Dose
Age 18+ –
  130mg daily (2 tablets)
Age 3-18 –
  65mg daily (1 tablet)**
1 month to 3 yrs. –
  32mg daily (½ tablet)
Birth to 1 month –
  16mg daily (¼ tablet)

For more information on treating infants, visit the U.S. Food and Drug Administration’s discussion of the topic at: www.fda.gov/cder/drugprepare/
kiprep65mg.htm
.


**Adolescents approaching adult size (approx.100+ lbs.) should receive the full adult dose (130 mg-two 65 mg tablets).
*Figures are based upon a Ukrainain study in CANCER published on 1st July 1999